文献速递前列腺癌

基于临床与多参数MRI参数的前列腺癌根治术候选患者风险分层:新型风险分组开发与外部验证

Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
PubMed 文献 · Eur Urol · 2021-08-13

本研究回顾性纳入7个国际中心2014–2020年间2565例接受根治性前列腺癌切除术的患者,整合临床与MRI参数构建预测早期生化复发(BCR)的列线图并外部验证,衍生出四个新风险组;新分组预测早期BCR的准确度(c-index 70%)高于EAU、CAPRA和STAR-CAP分组。

要点

  • 整合PSA、活检分级分组、MRI分期和病灶最大径的列线图外部验证区分度c-index为78%。
  • 新风险分组预测早期BCR的c-index为70%,优于EAU(64%)、CAPRA(63%)和STAR-CAP(67%)。
  • EAU低危与中危组3年无BCR生存率无差异(88% vs 87%,p=0.1)。

核心结论

  • 基于临床与影像参数构建并外部验证了四个新风险组,预测早期BCR准确度优于现有工具。

研究设计与样本

  • 回顾性多中心队列研究,纳入2014–2020年7个国际学术转诊中心2565例接受根治性前列腺切除术的前列腺癌患者。

主要发现

  • 总体3年无BCR生存率为84%。
  • 按EAU风险分组,低危200例(8%)、中危1834例(71%)、高危531例(21%)。
  • EAU低危与中危组3年无BCR生存率无差异(88% vs 87%;p=0.1)。
  • 列线图外部验证c-index为78%。
  • 新风险分组预测早期BCR的c-index为70%,高于EAU(64%)、CAPRA(63%)和STAR-CAP(67%)。

关键数值与推荐

  • 早期BCR定义为根治性前列腺切除术后3年内两次前列腺特异性抗原(PSA)≥0.2 ng/ml。
  • 预测变量包括PSA、活检分级分组、MRI分期和MRI病灶最大径。

临床怎么用

  • 新型分类简便且准确度更高,可辅助医生对根治性治疗候选患者进行术前咨询。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the key importance of magnetic resonance imaging (MRI) parameters, risk classification systems for biochemical recurrence (BCR) in prostate cancer (PCa) patients treated with radical prostatectomy (RP) are still based on clinical variables alone. OBJECTIVE: We aimed at developing and validating a novel classification integrating clinical and radiological parameters. DESIGN, SETTING, AND PARTICIPANTS: A retrospective multicenter cohort study was conducted between 2014 and 2020 across seven academic international referral centers. A total of 2565 patients treated with RP for PCa were identified. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Early BCR was defined as two prostate-specific antigen (PSA) values of ≥0.2 ng/ml within 3 yr after RP. Kaplan-Meier and Cox regressions tested time and predictors of BCR. Development and validation cohorts were generated from the overall patient sample. A model predicting early BCR based on Cox-derived coefficients represented the basis for a nomogram that was validated externally. Predictors consisted of PSA, biopsy grade group, MRI stage, and the maximum diameter of lesion at MRI. Novel risk categories were then identified. The Harrel's concordance index (c-index) compared the accuracy of our risk stratification with the European Association of Urology (EAU), Cancer of the Prostate Risk Assessment (CAPRA), and International Staging Collaboration for Cancer of the Prostate (STAR-CAP) risk groups in predicting early BCR. RESULTS AND LIMITATIONS: Overall, 200 (8%), 1834 (71%), and 531 (21%) had low-, intermediate-, and high-risk disease according to the EAU risk groups. The 3-yr overall BCR-free survival rate was 84%. No differences were observed in the 3-yr BCR-free survival between EAU low- and intermediate-risk groups (88% vs 87%; p = 0.1). The novel nomogram depicted optimal discrimination at external validation (c-index 78%). Four new risk categories were identified based on the predictors included in the Cox-based nomogram. This new risk classification had higher accuracy in predicting early BCR (c-index 70%) than the EAU, CAPRA, and STAR-CAP risk classifications (c-index 64%, 63%, and 67%, respectively). CONCLUSIONS: We developed and externally validated four novel categories based on clinical and radiological parameters to predict early BCR. This novel classification exhibited higher accuracy than the available tools. PATIENT SUMMARY: Our novel and straightforward risk classification outperformed currently available preoperative risk tools and should, therefore, assist physicians in preoperative counseling of men candidate to radical treatment for prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mazzone E, Gandaglia G, Ploussard G, et al. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. Eur Urol. 2021. PMID: 34399996. doi:10.1016/j.eururo.2021.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。